BackTempest Therapeutics Overview

Tempest Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for TPST.

Quarterly EBIT

-$27.72M
153.47% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$43.37M
2.83% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)